PHP Code

Using the PHP code extracts allows Academic Staff Profiles to be displayed in a number of different styles including the tabbed format shown below - the data is provided dynamically from the IRIS application, while maintaning the consistent look and feel of your site.

Prof John Collinge

Summary

John Collinge is Professor of Neurology and Head of the Department of Neurodegenerative Disease at the UCL Institute of Neurology, and Director of the MRC Prion Unit. He also directs the NHS National Prion Clinic at the adjacent National Hospital for Neurology and Neurosurgery. Professor Collinge trained in medicine at the University of Bristol and in neurology at St Mary’s Hospital and the National Hospital for Neurology and Neurosurgery in London. He is committed to highly multidisciplinary research and the seamless integration of basic laboratory and clinical research. He established the MRC Prion Unit at Imperial College in 1998 where he held the positions of Wellcome Senior Clinical Fellow and then Wellcome Principal Clinical Fellow. His laboratory demonstrated in 1996 that the new human prion disease, variant CJD, was caused by the same prion strain as that causing BSE in cattle and has been responsible for a number of key advances in the field. Professor Collinge has served on numerous Government advisory committees on prion disease at a national, European Union and international level. He is committed to public communication of the Unit’s research and gives many media interviews. He is a Founder Fellow of the Academy of Medical Sciences, a Fellow of the Royal Society and was awarded a CBE for services to medical research.

Research Summary

The Department of Neurodegenerative Disease’s research portfolio encompasses prion diseases (predominantly within the embedded MRC Prion Unit), Alzheimer’s disease and related disorders, Huntington’s disease, motor neurone disease and frontotemporal dementia and studies of the pathways of cellular senescence. The research philosophy is to combine basic and clinical translational research; many of the key contributions towards understanding the basic biology of these diseases have come from clinical and neuropathological observations, and efficient translation of basic laboratory research to the clinic is essential to provide benefits for patients at the earliest opportunity.

The MRC Prion Unit was established in 1998 and is located at the UCL Institute of Neurology where it is closely integrated with the University Department of Neurodegenerative Disease. The Unit was formed to provide a national centre of excellence with all necessary facilities to pursue a major long-term research strategy in prion and related diseases. 

Prions, unlike other infectious agents or germs, appear to lack their own genes and consist of aggregated misshapen forms of one of the body’s own proteins, the prion protein or PrP. Despite lacking genes, prions can exist as distinct strains with quite different properties. These unique features have wide implications in biology and evolution, and prions and prion diseases are of intense international research interest. However, in addition to the importance of this basic science, the Unit’s mission is also to tackle key public health issues posed by bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD).

It is becoming increasingly clear that other much commoner degenerative brain diseases, such as Alzheimer’s and Parkinson’s disease, also involve accumulation of rogue or abnormal forms of one or more of the body’s proteins resulting in damage to brain cells. Prion diseases, in addition to their intrinsic interest and importance, can be considered a paradigm for these other “protein misfolding” diseases. 

Our research programmes are highly multidisciplinary and focus both on areas of public health concern and a long-term approach to the understanding of prion disease. They include studies of molecular structure, genetics, biochemistry, immunology, cell and animal models, and clinical research - including treatment trials. Two major programmes to develop novel therapies are underway.

Research Activities

  • Cellular mechanisms underlying neurodegeneration
  • Neurodegenerative Disease
  • Neurological disease

Recent Publications

Displaying 50 most recent publications. For the full list please visit UCL Discovery

  1. Harold D,Abraham R,Hollingworth P,Sims R,Gerrish A,Hamshere ML,Pahwa JS,Moskvina V,Dowzell K,Williams A,Jones N,Thomas C,Stretton A,Morgan AR,Lovestone S,Powell J,Proitsi P,Lupton MK,Brayne C,Rubinsztein DC,Gill M,Lawlor B,Lynch A,Morgan K,Brown KS,Passmore PA,Craig D,McGuinness B,Todd S,Holmes C,Mann D,Smith AD,Love S,Kehoe PG,Hardy J,Mead S,Fox N,Rossor M,Collinge J,Maier W,Jessen F,Schürmann B,Heun R,van den Bussche H,Heuser I,Kornhuber J,Wiltfang J,Dichgans M,Frölich L,Hampel H,Hüll M,Rujescu D,Goate AM,Kauwe JS,Cruchaga C,Nowotny P,Morris JC,Mayo K,Sleegers K,Bettens K,Engelborghs S,De Deyn PP,Van Broeckhoven C,Livingston G,Bass NJ,Gurling H,McQuillin A,Gwilliam R,Deloukas P,Al-Chalabi A,Shaw CE,Tsolaki M,Singleton AB,Guerreiro R,Mühleisen TW,Nöthen MM,Moebus S,Jöckel KH,Klopp N,Wichmann HE,Carrasquillo MM,Pankratz VS,Younkin SG,Holmans PA,O'Donovan M,Owen MJ,Williams J (2013) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet, 45(6), 712. 10.1038/ng0613-712a.
  2. Reiniger L,Mirabile I,Lukic A,Linehan J,Groves M,Rudge P,Collinge J,Mead S,Brandner S (2013) Filamentous white matter prion protein deposition is a distinctive feature of multiple inherited prion diseases NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 39, 23 - 24.
  3. Thompson AG,Lowe J,Fox Z,Lukic A,Porter MC,Ford L,Gorham M,Gopalakrishnan GS,Rudge P,Walker AS,Collinge J,Mead S (2013) The Medical Research Council prion disease rating scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain, 136(Pt 4), 1116 - 1127. 10.1093/brain/awt048.
  4. De Vita E,Ridgway GR,Scahill RI,Caine D,Rudge P,Yousry TA,Mead S,Collinge J,Jäger HR,Thornton JS,Hyare H (2013) Multiparameter MR Imaging in the 6-OPRI Variant of Inherited Prion Disease. AJNR Am J Neuroradiol. 10.3174/ajnr.A3504.
  5. Angus-Leppan H,Rudge P,Mead S,Collinge J,Vincent A (2013) Autoantibodies in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurol, 1 - 4. 10.1001/jamaneurol.2013.2077.
  6. Beck J,Poulter M,Hensman D,Rohrer JD,Mahoney CJ,Adamson G,Campbell T,Uphill J,Borg A,Fratta P,Orrell RW,Malaspina A,Rowe J,Brown J,Hodges J,Sidle K,Polke JM,Houlden H,Schott JM,Fox NC,Rossor MN,Tabrizi SJ,Isaacs AM,Hardy J,Warren JD,Collinge J,Mead S (2013) Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet, 92(3), 345 - 353. 10.1016/j.ajhg.2013.01.011.
  7. Guerreiro R,Wojtas A,Bras J,Carrasquillo M,Rogaeva E,Majounie E,Cruchaga C,Sassi C,Kauwe JS,Younkin S,Hazrati L,Collinge J,Pocock J,Lashley T,Williams J,Lambert JC,Amouyel P,Goate A,Rademakers R,Morgan K,Powell J,St George-Hyslop P,Singleton A,Hardy J,Alzheimer Genetic Analysis G (2013) TREM2 variants in Alzheimer's disease N Engl J Med, 368, 117 - 127. 10.1056/NEJMoa1211851.
  8. Akhtar S,Grizenkova J,Wenborn A,Hummerich H,Fernandez de Marco M,Brandner S,Collinge J,Lloyd SE (2013) Sod1 deficiency reduces incubation time in mouse models of prion disease. PLoS One, 8(1), e54454. 10.1371/journal.pone.0054454.
  9. Guerreiro R,Wojtas A,Bras J,Carrasquillo M,Rogaeva E,Majounie E,Cruchaga C,Sassi C,Kauwe JS,Younkin S,Hazrati L,Collinge J,Pocock J,Lashley T,Williams J,Lambert JC,Amouyel P,Goate A,Rademakers R,Morgan K,Powell J,St George-Hyslop P,Singleton A,Hardy J,Alzheimer Genetic Analysis Group (2013) TREM2 variants in Alzheimer's disease. N Engl J Med, 368(2), 117 - 127. 10.1056/NEJMoa1211851.
  10. Lloyd SE,Mead S,Collinge J (2013) Genetics of prion diseases. Curr Opin Genet Dev. 10.1016/j.gde.2013.02.012.
  11. Carswell C,Thompson A,Lukic A,Stevens J,Rudge P,Mead S,Collinge J,Hyare H (2012) MRI findings are often missed in the diagnosis of Creutzfeldt-Jakob disease. BMC Neurol, 12, 153. 10.1186/1471-2377-12-153.
  12. Hyare H,Ramlackhansingh A,Gelosa G,Edison P,Rudge P,Brandner S,Brooks DJ,Collinge J,Mead S (2012) 11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry, 83(3), 340 - 341. 10.1136/jnnp.2010.233692.
  13. Grizenkova J,Akhtar S,Hummerich H,Tomlinson A,Asante EA,Wenborn A,Fizet J,Poulter M,Wiseman FK,Fisher EM,Tybulewicz VL,Brandner S,Collinge J,Lloyd SE (2012) Overexpression of the Hspa13 (Stch) gene reduces prion disease incubation time in mice. Proc Natl Acad Sci U S A, 109(34), 13722 - 13727. 10.1073/pnas.1208917109.
  14. Carswell C,Rañopa M,Pal S,Macfarlane R,Siddique D,Thomas D,Webb T,Wroe S,Walker S,Darbyshire J,Collinge J,Mead S,Rudge P (2012) Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1. Dement Geriatr Cogn Dis Extra, 2(1), 286 - 297.
  15. Kloehn P,Castro-Seoane R,Hummerich H,Sweeting T,Tattum H,Linehan J,de Marco MF,Brandner S,Collinge J (2012) Plasmacytoid dendritic cells sequester high prion titers at early stages of prion infection PRION, 6, 7 - 7.
  16. Quarterman E,Pannell M,Adams N,Farrow M,Collinge J (2012) High throughput screen of pharmacologically active compounds using chronically infected neuroblastoma (PK1) cells PRION, 6, 102 - 102.
  17. Collinge J (2012) Prion propagation and its wider implications PRION, 6, 1 - 1.
  18. Hyare H,Ramlackhansingh A,Gelosa G,Edison P,Rudge P,Brandner S,Brooks DJ,Collinge J,Mead S (2012) C-11-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt-Jakob disease JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83(3), 340 - 341.
  19. Porter MC,Hyare H,De Vita E,Thompson A,Lukic A,Yousry T,Rudge P,Mead S,Collinge J,Thornton J (2012) VOXELWISE ANALYSIS OF CEREBRAL DIFFUSION TENSOR IMAGING IN PRION DISEASES JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83(3). 10.1136/jnnp-2011-301993.64.
  20. Ghazi-Noori S,Froud KE,Mizielinska S,Powell C,Smidak M,Fernandez de Marco M,O'Malley C,Farmer M,Parkinson N,Fisher EM,Asante EA,Brandner S,Collinge J,Isaacs AM (2012) Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain, 135(Pt 3), 819 - 832. 10.1093/brain/aws006.
  21. Mahoney CJ,Beck J,Rohrer JD,Lashley T,Mok K,Shakespeare T,Yeatman T,Warrington EK,Schott JM,Fox NC,Rossor MN,Hardy J,Collinge J,Revesz T,Mead S,Warren JD (2012) Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain, 135(Pt 3), 736 - 750. 10.1093/brain/awr361.
  22. Castro-Seoane R,Hummerich H,Sweeting T,Tattum MH,Linehan JM,Fernandez de Marco M,Brandner S,Collinge J,Klöhn PC (2012) Plasmacytoid dendritic cells sequester high prion titres at early stages of prion infection. PLoS Pathog, 8(2), e1002538. 10.1371/journal.ppat.1002538.
  23. Klöhn PC,Farmer M,Linehan JM,O'Malley C,Fernandez de Marco M,Taylor W,Farrow M,Khalili-Shirazi A,Brandner S,Collinge J (2012) PrP antibodies do not trigger mouse hippocampal neuron apoptosis. Science, 335(6064), 52. 10.1126/science.1215579.
  24. Mead S,Uphill J,Beck J,Poulter M,Campbell T,Lowe J,Adamson G,Hummerich H,Klopp N,Rückert IM,Wichmann HE,Azazi D,Plagnol V,Pako WH,Whitfield J,Alpers MP,Whittaker J,Balding DJ,Zerr I,Kretzschmar H,Collinge J (2012) Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. Hum Mol Genet, 21(8), 1897 - 1906. 10.1093/hmg/ddr607.
  25. Beck J,Collinge J,Mead S (2012) Prion protein gene M232R variation is probably an uncommon polymorphism rather than a pathogenic mutation. Brain, 135(Pt 2), e209. 10.1093/brain/awr294.
  26. Gerrish A,Russo G,Richards A,Moskvina V,Ivanov D,Harold D,Sims R,Abraham R,Hollingworth P,Chapman J,Hamshere M,Pahwa JS,Dowzell K,Williams A,Jones N,Thomas C,Stretton A,Morgan AR,Lovestone S,Powell J,Proitsi P,Lupton MK,Brayne C,Rubinsztein DC,Gill M,Lawlor B,Lynch A,Morgan K,Brown KS,Passmore PA,Craig D,McGuinness B,Todd S,Johnston JA,Holmes C,Mann D,Smith AD,Love S,Kehoe PG,Hardy J,Mead S,Fox N,Rossor M,Collinge J,Maier W,Jessen F,Kölsch H,Heun R,Schürmann B,van den Bussche H,Heuser I,Kornhuber J,Wiltfang J,Dichgans M,Frölich L,Hampel H,Hüll M,Rujescu D,Goate AM,Kauwe JS,Cruchaga C,Nowotny P,Morris JC,Mayo K,Livingston G,Bass NJ,Gurling H,McQuillin A,Gwilliam R,Deloukas P,Davies G,Harris SE,Starr JM,Deary IJ,Al-Chalabi A,Shaw CE,Tsolaki M,Singleton AB,Guerreiro R,Mühleisen TW,Nöthen MM,Moebus S,Jöckel KH,Klopp N,Wichmann HE,Carrasquillo MM,Pankratz VS,Younkin SG,Jones L,Holmans PA,O'Donovan MC,Owen MJ,Williams J (2012) The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis, 28(2), 377 - 387. 10.3233/JAD-2011-110824.
  27. Alner K,Hyare H,Mead S,Rudge P,Wroe S,Rohrer JD,Ridgway GR,Ourselin S,Clarkson M,Hunt H,Fox NC,Webb T,Collinge J,Cipolotti L (2012) Distinct neuropsychological profiles correspond to distribution of cortical thinning in inherited prion disease caused by insertional mutation. J Neurol Neurosurg Psychiatry, 83(1), 109 - 114. 10.1136/jnnp-2011-300167.
  28. McNaughton D,Knight W,Guerreiro R,Ryan N,Lowe J,Poulter M,Nicholl DJ,Hardy J,Revesz T,Lowe J,Rossor M,Collinge J,Mead S (2012) Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiol Aging, 33(2), 426.e13 - 426.e21. 10.1016/j.neurobiolaging.2010.10.010.
  29. Collinge J (2012) Cell biology. The risk of prion zoonoses. Science, 335(6067), 411 - 413. 10.1126/science.1218167.
  30. Mead S,Beck J,Poulter M,Rohrer J,Adamson G,Hensman D,Polke J,Campbell T,Uphill J,Borg A,Tabrizi S,Isaacs A,Hardy J,Warren J,Collinge J (2012) Large C9ORF72 hexanucleotide expansions arise spontaneously in the healthy population but can be distinguished from pathogenic mutations by Sothern Blotting DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 33, 285 - 286.
  31. Begum R,Lloyd S,Collinge J (2011) Functional analysis of a prion disease modifier linked to incubation time GENETICS RESEARCH, 93(6), 438 - 438.
  32. Goold R,Rabbanian S,Sutton L,Andre R,Arora P,Moonga J,Clarke AR,Schiavo G,Jat P,Collinge J,Tabrizi SJ (2011) Rapid cell-surface prion protein conversion revealed using a novel cell system NAT COMMUN, 2. 10.1038/ncomms1282.
  33. Rollinson S,Rohrer JD,van der Zee J,Sleegers K,Mead S,Engelborghs S,Collinge J,De Deyn PP,Mann DM,Van Broeckhoven C,Pickering-Brown SM (2011) No association of PGRN 3'UTR rs5848 in frontotemporal lobar degeneration. Neurobiol Aging, 32(4), 754 - 755. 10.1016/j.neurobiolaging.2009.04.009.
  34. Mead S,Ranopa M,Gopalakrishnan GS,Thompson AG,Rudge P,Wroe S,Kennedy A,Hudson F,MacKay A,Darbyshire JH,Collinge J,Walker AS (2011) PRION-1 scales analysis supports use of functional outcome measures in prion disease. Neurology, 77(18), 1674 - 1683. 10.1212/WNL.0b013e3182364890.
  35. Sims R,Dwyer S,Harold D,Gerrish A,Hollingworth P,Chapman J,Jones N,Abraham R,Ivanov D,Pahwa JS,Moskvina V,Dowzell K,Thomas C,Stretton A,Lovestone S,Powell J,Proitsi P,Lupton MK,Brayne C,Rubinsztein DC,Gill M,Lawlor B,Lynch A,Morgan K,Brown KS,Passmore PA,Craig D,McGuiness B,Todd S,Johnston JA,Holmes C,Mann D,Smith AD,Love S,Kehoe PG,Hardy J,Mead S,Fox N,Rossor M,Collinge J,Livingston G,Bass NJ,Gurling H,McQuillin A,Jones L,Holmans PA,O'Donovan M,Owen MJ,Williams J (2011) No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet, 156B(7), 764 - 771. 10.1002/ajmg.b.31216.
  36. Deriziotis P,André R,Smith DM,Goold R,Kinghorn KJ,Kristiansen M,Nathan JA,Rosenzweig R,Krutauz D,Glickman MH,Collinge J,Goldberg AL,Tabrizi SJ (2011) Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. EMBO J, 30(15), 3065 - 3077. 10.1038/emboj.2011.224.
  37. Kaski DN,Pennington C,Beck J,Poulter M,Uphill J,Bishop MT,Linehan JM,O'Malley C,Wadsworth JD,Joiner S,Knight RS,Ironside JW,Brandner S,Collinge J,Mead S (2011) Inherited prion disease with 4-octapeptide repeat insertion: disease requires the interaction of multiple genetic risk factors. Brain, 134(Pt 6), 1829 - 1838. 10.1093/brain/awr079.
  38. Hollingworth P,Harold D,Sims R,Gerrish A,Lambert JC,Carrasquillo MM,Abraham R,Hamshere ML,Pahwa JS,Moskvina V,Dowzell K,Jones N,Stretton A,Thomas C,Richards A,Ivanov D,Widdowson C,Chapman J,Lovestone S,Powell J,Proitsi P,Lupton MK,Brayne C,Rubinsztein DC,Gill M,Lawlor B,Lynch A,Brown KS,Passmore PA,Craig D,McGuinness B,Todd S,Holmes C,Mann D,Smith AD,Beaumont H,Warden D,Wilcock G,Love S,Kehoe PG,Hooper NM,Vardy ER,Hardy J,Mead S,Fox NC,Rossor M,Collinge J,Maier W,Jessen F,Rüther E,Schürmann B,Heun R,Kölsch H,van den Bussche H,Heuser I,Kornhuber J,Wiltfang J,Dichgans M,Frölich L,Hampel H,Gallacher J,Hüll M,Rujescu D,Giegling I,Goate AM,Kauwe JS,Cruchaga C,Nowotny P,Morris JC,Mayo K,Sleegers K,Bettens K,Engelborghs S,De Deyn PP,Van Broeckhoven C,Livingston G,Bass NJ,Gurling H,McQuillin A,Gwilliam R,Deloukas P,Al-Chalabi A,Shaw CE,Tsolaki M,Singleton AB,Guerreiro R,Mühleisen TW,Nöthen MM,Moebus S,Jöckel KH,Klopp N,Wichmann HE,Pankratz VS,Sando SB,Aasly JO,Barcikowska M,Wszolek ZK,Dickson DW,Graff-Radford NR,Petersen RC,Alzheimer's Disease Neuroimaging Initiative ,van Duijn CM,Breteler MM,Ikram MA,DeStefano AL,Fitzpatrick AL,Lopez O,Launer LJ,Seshadri S,CHARGE consortium ,Berr C,Campion D,Epelbaum J,Dartigues JF,Tzourio C,Alpérovitch A,Lathrop M,EADI1 consortium ,Feulner TM,Friedrich P,Riehle C,Krawczak M,Schreiber S,Mayhaus M,Nicolhaus S,Wagenpfeil S,Steinberg S,Stefansson H,Stefansson K,Snaedal J,Björnsson S,Jonsson PV,Chouraki V,Genier-Boley B,Hiltunen M,Soininen H,Combarros O,Zelenika D,Delepine M,Bullido MJ,Pasquier F,Mateo I,Frank-Garcia A,Porcellini E,Hanon O,Coto E,Alvarez V,Bosco P,Siciliano G,Mancuso M,Panza F,Solfrizzi V,Nacmias B,Sorbi S,Bossù P,Piccardi P,Arosio B,Annoni G,Seripa D,Pilotto A,Scarpini E,Galimberti D,Brice A,Hannequin D,Licastro F,Jones L,Holmans PA,Jonsson T,Riemenschneider M,Morgan K,Younkin SG,Owen MJ,O'Donovan M,Amouyel P,Williams J (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet, 43(5), 429 - 435. 10.1038/ng.803.
  39. Rohrer JD,Warren JD,Reiman D,Uphill J,Beck J,Collinge J,Rossor MN,Isaacs AM,Mead S (2011) A novel exon 2 I27V VCP variant is associated with dissimilar clinical syndromes. J Neurol, 258(8), 1494 - 1496. 10.1007/s00415-011-5966-4.
  40. Wadsworth JD,Dalmau-Mena I,Joiner S,Linehan JM,O'Malley C,Powell C,Brandner S,Asante EA,Ironside JW,Hilton DA,Collinge J (2011) Effect of fixation on brain and lymphoreticular vCJD prions and bioassay of key positive specimens from a retrospective vCJD prevalence study. J Pathol, 223(4), 511 - 518. 10.1002/path.2821.
  41. Reiniger L,Lukic A,Linehan J,Rudge P,Collinge J,Mead S,Brandner S (2011) Prion protein-induced tau phosphorylation: insight into a universal mechanism triggered by cerebral amyloid NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 37, 13 - 13.
  42. Jones L,Holmans PA,Hamshere ML,Harold D,Moskvina V,Ivanov D,Pocklington A,Abraham R,Hollingworth P,Sims R,Gerrish A,Pahwa JS,Jones N,Stretton A,Morgan AR,Lovestone S,Powell J,Proitsi P,Lupton MK,Brayne C,Rubinsztein DC,Gill M,Lawlor B,Lynch A,Morgan K,Brown KS,Passmore PA,Craig D,McGuinness B,Todd S,Holmes C,Mann D,Smith AD,Love S,Kehoe PG,Mead S,Fox N,Rossor M,Collinge J,Maier W,Jessen F,Schürmann B,van den Bussche H,Heuser I,Peters O,Kornhuber J,Wiltfang J,Dichgans M,Frölich L,Hampel H,Hüll M,Rujescu D,Goate AM,Kauwe JS,Cruchaga C,Nowotny P,Morris JC,Mayo K,Livingston G,Bass NJ,Gurling H,McQuillin A,Gwilliam R,Deloukas P,Al-Chalabi A,Shaw CE,Singleton AB,Guerreiro R,Mühleisen TW,Nöthen MM,Moebus S,Jöckel KH,Klopp N,Wichmann HE,Rüther E,Carrasquillo MM,Pankratz VS,Younkin SG,Hardy J,O'Donovan MC,Owen MJ,Williams J (2011) Correction: genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One, 6(2). 10.1371/annotation/a0bb886d-d345-4a20-a82e-adce9b047798.
  43. Edgeworth JA,Sicilia A,Linehan J,Brandner S,Jackson GS,Collinge J (2011) A standardized comparison of commercially available prion decontamination reagents using the Standard Steel-Binding Assay. J Gen Virol, 92(Pt 3), 718 - 726. 10.1099/vir.0.027201-0.
  44. Stevens JC,Beck J,Lukic A,Ryan N,Abbs S,Collinge J,Fox NC,Mead S (2011) Familial Alzheimer's disease and inherited prion disease in the UK are poorly ascertained. J Neurol Neurosurg Psychiatry, 82(9), 1054 - 1057. 10.1136/jnnp.2009.199653.
  45. Akhtar S,Wenborn A,Brandner S,Collinge J,Lloyd SE (2011) Sex effects in mouse prion disease incubation time. PLoS One, 6(12), e28741. 10.1371/journal.pone.0028741.
  46. Wadsworth JDF,Collinge J (2011) Molecular pathology of human prion disease ACTA NEUROPATHOL, 121(1), 69 - 77. 10.1007/s00401-010-0735-5.
  47. Carswell C,Drynda R,Martins S,Clarke A,Brandner S,Mead S,Collinge J,Khalili-Shirazi A (2011) PAW35 Anti-prion protein monoclonal antibodies at low doses effectively treat prion disease in mice without side-effects (vol 81, pg e33, 2010) J NEUROL NEUROSUR PS, 82(7), 826 - 826. 10.1136/jnnp.2010.226340.63corr1.
  48. Freir DB,Nicoll AJ,Klyubin I,Panico S,Mc Donald JM,Risse E,Asante EA,Farrow MA,Sessions RB,Saibil HR,Clarke AR,Rowan MJ,Walsh DM,Collinge J (2011) Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun, 2, 336. 10.1038/ncomms1341.
  49. Lloyd S,Mead S,Collinge J (2011) Genetics of prion disease. Top Curr Chem, 305, 1 - 22. 10.1007/128_2011_157.
  50. Sandberg MK,Al-Doujaily H,Sharps B,Clarke AR,Collinge J (2011) Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature, 470(7335), 540 - 542. 10.1038/nature09768.

Biography

John Collinge is Professor of Neurology and Head of the Department of Neurodegenerative Disease at the UCL Institute of Neurology, and Director of the MRC Prion Unit. He also directs the NHS National Prion Clinic at the adjacent National Hospital for Neurology and Neurosurgery. Professor Collinge trained in medicine at the University of Bristol and in neurology at St Mary’s Hospital and the National Hospital for Neurology and Neurosurgery in London. He is committed to highly multidisciplinary research and the seamless integration of basic laboratory and clinical research. He established the MRC Prion Unit at Imperial College in 1998 where he held the positions of Wellcome Senior Clinical Fellow and then Wellcome Principal Clinical Fellow. His laboratory demonstrated in 1996 that the new human prion disease, variant CJD, was caused by the same prion strain as that causing BSE in cattle and has been responsible for a number of key advances in the field. Professor Collinge has served on numerous Government advisory committees on prion disease at a national, European Union and international level. He is committed to public communication of the Unit’s research and gives many media interviews. He is a Founder Fellow of the Academy of Medical Sciences, a Fellow of the Royal Society and was awarded a CBE for services to medical research.

Qualifications

  • : Member of the Royal College of Physicians, Royal College of Physicians
  • 1998: Fellow of the Royal College of Physicians, Royal College of Physicians
  • 1992: Doctor of Medicine, University of Bristol
  • 1984: Bachelor of Medicine, Bachelor of Surgery, University of Bristol
  • 1981: Bachelor of Science (Honours), University of Bristol